Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
暂无分享，去创建一个
J. Lechner-Scott | M. Onofrj | M. Slee | H. Butzkueven | S. Khoury | J. Kuhle | F. Patti | A. van der Walt | G. Izquierdo | C. Boz | Chao Zhu | R. Karabudak | A. Prat | S. Ozakbas | D. Horáková | T. Kalincik | V. van Pesch | R. Alroughani | V. Jokubaitis | O. Skibina | R. Macdonell | S. Hodgkinson | M. Monif | I. Roos | J. Prevost | Daniele Merlo | Eva Kubala Havrdova | Zhen Zhou | M. Barnett | E. Kubala Havrdova